Omeros (OMER) stock

Therapeutics for diseases , market cap $1.2B

Therapeutics for diseases

Worth $1.2B

$16.80

-0.71%

As of 9:45 AM ET, delayed 15+ min · Live for Pro members

Why is OMER down?

Down 3% on Nov 2, and still 8% under its Oct 30 close.

It filed a report with the SEC on a change of officers after the close on Oct 30.

Sources: Price history, Nov 2, 2026; SEC filing, Oct 30, 2026

Tell me next time OMER moves

Free account, no card. An optional alert when OMER moves or its score changes.

Or see it live, free for 24 hours. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

Below Average

In its industry

#37of 90

Pharma

Checks firing

1of 14

Choppy

From 52-week high

-20.9%

under its best in a year

OMER's Quality Score was unchanged on Fri, Nov 6, at 4.

Follow OMER's trial news. Pro members can get an alert when Omeros files news, and see its trials, share raises, and its CEO's filings.

Get an alert when OMER files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“We expect to be able start enrollment in the inpatient clinical trial by year-end 2026.”Trial start · SEC filing · Aug 12

Cash$132M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

Key facts on OMER

Key facts on OMER
Holding it back	Free cash flow -$69M 6% of its market value
Latest filing	8-K, Oct 30 Reported a change of officers or directors

1 more reason behind OMER's 4, free with an account →4 more reasons behind OMER's 4, for Pro members.

OMER in the news

ReportExpected to report Thursday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +14.7% on average. Past reports ›

Cash$132M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

OMER catalysts

Coming up

After its last 4 reports it closed +14.7% on average, higher 3 of 4 times.

4 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for OMER, and how long its cash lasts

Next step the company has named

End of 2026“We expect to be able start enrollment in the inpatient clinical trial by year-end 2026.”Trial start · SEC filing · Aug 12

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaPhase 2 · Active · 25 people · main data estimated Dec 2026 · NCT06298955

1 more trial, 1 more milestone and 32 filings, for Pro members.

Cash runway Jun 30 balance sheet

$132M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 14, 2025)
At-the-market share sales program (S-3ASR, filed Nov 14, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

VP, Finance & CAO David J. Borges sold 20,000 shares on Sep 23, under a planned sale. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Gregory Demopulos buys or sells

For Pro members: every trade, and Gregory Demopulos’s 5 filings and quotes.

Get an alert when OMER files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why OMER scores 4

Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

+2Long-term trend above a rising 200-⁠day average
+2Run-up 155% over 12 months

Chart checks adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on OMER and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:45 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How OMER ranks in Pharma

OMER is #37 of 90 by Quality Score.

How OMER ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	NVSNovartis		Open for its score
	OCSOculis		Open for its score
	OPKOpko Health		Open for its score
	PBHPrestige Consumer Healthcare		Open for its score
37	OMEROmeros	1/14	4

When does OMER report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 3 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+14.4%-7.7%+26.6%

Mar 31May 13Aug 12

Reported	When	Gap	Reaction	5 days
Aug 12, 2026After close	After close	+21.4%	+26.6%	+34.1%
May 13, 2026After close	After close	+1.1%	-7.7%	-13.9%
Mar 31, 2026After close	After close	+7.2%	+14.4%	+9.0%

OMER closed higher after 3 of its last 4 reports.

All 4 reports, and OMER's Quality Score going into each

Everyone reporting earnings this week

OMER has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on OMER, and all 14 on every stock.Get in free →

OMER RSI today: 43.0, below its 50-day, above its 200-day

Not scored

RSI 43.0, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on OMER

What it does and how it makes money3 findings"Under our exclusive license agreements with the University of Leicester and MRC, we have agreed to pay royalties to each of the University of Leicester and MRC that are a percentage of any proceeds we receive from the licensed MASP-2 technology during the terms of the agreements." (10-K for fiscal 2020)SEC filing · Mar 1, 2021"Under the settlement agreements, we granted each of Par and Lupin a non-exclusive, non-sublicensable license to make, sell and distribute a generic version of OMIDRIA between their applicable entry dates and the latest expiration of our U.S. patents related to OMIDRIA (i.e., October 23, 2033)." (10-K for fiscal 2020)SEC filing · Mar 1, 2021
Where it stands3 findingsFor Pro members3 findings on where OMER stands: its cash, debt, and share count, for Pro members
What changed in its filings3 findingsA new heading in its "Risk Factors" this year: "Clinical trials evaluating narsoplimab for treatment of COVID-19 may be unsuccessful and, even if successful, we may be unable to manufacture narsoplimab in quantities adequate to meet demand." (10-K for fiscal 2020; not in fiscal 2019's)SEC filing · Mar 1, 2021, against the one of Mar 2, 2020One distributor made up 32% of its revenue in fiscal 2020, up from 29% in fiscal 2019; another made up 17%, down from 22% in fiscal 2019.SEC filing · Mar 1, 2021
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades OMER, for Pro members

7 more findings on OMER, each with its source, for Pro members.

OMER share count over time

Shares: 23.1% more than a year ago (to Jun 30).

Shares of OMER outstanding, as filed
Shares outstanding	As of
72.4M	Aug 7, 2026
72.4M	May 11, 2026
72M	Mar 27, 2026
70.9M	Nov 12, 2025

Offerings, shelves, and splits of OMER, from its filings
From its filings	Filed
Set up an at-the-market program for up to $150M of shares, about 12% of its market value	Nov 14, 2025
Registered shares for a later sale (S-3ASR)	Nov 14, 2025
Priced a sale of shares	Jul 25, 2025

OMER insider trades

3 insiders sold $1.5M across 6 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellPeter B. Cancelmo$466KVP, General Counselat $18.65 on Aug 28, filed Sep 1

SellPeter B. CancelmoVP, General Counsel$466Kat $18.65 on Aug 28, filed Sep 1

All 6 insider filings on OMER from the last six months, for Pro members.

All OMER insider trades

OMER's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Gregory A. DemopulosChairman, CEO & President · no trades on file
David J. BorgesVP, Finance & CAO · 7 trades
Peter B. CancelmoVP, General Counsel · 2 trades
Arnold C. HanishDirector · 3 trades
Thomas J. CableDirector · 2 trades

See insider trades by person

Which ETFs hold OMER?

In ETFs: OMER is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Omeros

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

175 employeesSeattle, WAomeros.com

What Omeros says it competes with

“The pharmaceutical and biotechnology industry is highly competitive and characterized by a number of established, large pharmaceutical and biotechnology companies as well as smaller companies like ours.”

From its annual report, SEC filing · Mar 1, 2021

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on OMER and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn OMER's score around: 6 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 1Peter B. Cancelmo sold OMER$466K at $18.65, filed Sep 1

Alerts are optional.

See OMER's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: OMER's Quality Score is 4 (Below Average), #37 of 90 in Pharma. Insiders sold $1.5M in the last 6 months (Form 4).

What does OMER's Quality Score say?

OMER scores 4 today, which Breakaway calls Below Average. It is #37 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 3% on Nov 2, and still 8% under its Oct 30 close. Shares: 23.1% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OMER's Quality Score?

OMER scores 4 today, which Breakaway calls Below Average (0 to 5). That is #37 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OMER's 4.

Are insiders buying OMER?

3 insiders sold $1.5M across 6 filings in the last 6 months. No open-⁠market buys on record. The newest is Peter B. Cancelmo, VP, General Counsel, who sold $466K on Aug 28. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.